Aurealis Therapeutics logo

Aurealis Therapeutics

Multi-target cell and gene therapies for unmet medical needs.

17 employees · est. 2015 · Kuopio, Finland

VS
Vyriad logo

Vyriad

Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deliver genes directly to cells.

51 employees · est. 2015 · Rochester, United States

Vyriad is the larger of the two.

Side-by-Side Comparison

Aurealis Therapeutics Vyriad
Founded
2015 2015
Headquarters
Kuopio, Finland Rochester, United States
Employees
17 51 larger
Industry
Biotechnology, Health and Wellness, Pharmaceutical Biotechnology
Funding Stage
Series A Series B
Total Funding
$10.00M $88.38M
Funding Rounds
1 5
Services
Not tracked yet Development of Viral Platforms, Manufacturing of Genetic Therapies, Preclinical and Clinical Trial Management, Collaborative Research and Development
Target Customers
Not tracked yet Medical Institutions, Pharmaceutical Companies, Research Organizations, Healthcare Organizations
Taxonomy
Cell And Gene Therapy, Recombinant Live Biotherapeutic, Chronic Wounds, Oncology, Advanced Therapy Medicinal Product, Inflammation, Oncolytic Bacteria Biotech, Genetic Therapies, Oncolytic Virotherapy, Viral Vectors, Gene Editing, Cancer Treatment, Phase 1-2 Clinical Studies, Targeted Cell Therapy, Immuno-Oncology, Clinical Research Collaboration, Proprietary Oncolytic Virus, Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Squamous Cell Carcinoma
Website
aurealistherapeutics.com vyriad.com
Aurealis Therapeutics logo

About Aurealis Therapeutics

Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company that focuses on developing multi-target cell and gene therapies to address unmet medical needs in areas such as Chronic Wounds, deadly Cancers, and Inflammation. The company's platform is based on genetically modified saf...

Vyriad logo

About Vyriad

Vyriad, a United States-based clinical-stage biotech company, is making strides in the biotechnology sector by pioneering targeted genetic therapies. These therapies are designed to deliver genes directly to cells using engineered viruses, viral vectors, and envelope glycoproteins. The company's tec...

We will tell you when either one moves

BounceWatch watches Aurealis Therapeutics and Vyriad for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Aurealis Therapeutics and Vyriad — by email.

Frequently Asked Questions

Aurealis Therapeutics — Multi-target cell and gene therapies for unmet medical needs.. Vyriad — Vyriad is a clinical-stage biotech company developing targeted genetic therapies that deliver genes directly to cells.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Aurealis Therapeutics has raised $10.00M while Vyriad has raised $88.38M.
Aurealis Therapeutics and Vyriad operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Aurealis Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Aurealis Therapeutics on 12 Sep 2024, and Vyriad on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy